Photographer: Kobi Wolf / Bloomberg
Photographer: Kobi Wolf / Bloomberg
Israel, with the highest proportion of citizens vaccinated against Covid-19 in the world, found that it took three weeks for the Pfizer Inc.-BioNTech fired SE to start preventing new cases and hospitalization.
Researchers in the Middle East country said Wednesday’s initial comments from a national vaccination program that began December. 20. There has been an improvement in the number of new cases and patients in hospital 21 days after the vaccination campaign, the scientists said, noting that the real-life effects of vaccines may take longer than expected. has been proven in clinical trials.
“To our knowledge, no study to date has examined the impact of the vaccination campaign on the population level and its impact on patterns of distributed dynamics,” said scientists from Weizmann Institute of Science in Rehovot said. “As Israel was one of the first countries to implement a vaccination campaign at this stage, we believe this measure could be of great interest to many countries around the world.”
The Israeli vaccination campaign began just before SARS-CoV-2 snoring became more volatile, fueling infections and leading to a third lockout on Jan. 8. On Tuesday, 28% of Israelis – including three-quarters of those 60 or older – had either received two doses of the vaccine or recovered from an infection. At its peak, 229,508 doses were given in a single day.
Read more: Covid-19 Bloomberg vaccine detector
Efficacy may differ slightly from clinical trial data in real-world situations for a number of reasons, the researchers said. Logistics, including cooling, storage, transportation and administration of the vaccines at the time of imperfect rapid delivery, may reduce efficiency, they said.
The U.S. Centers for Disease Control and Prevention recommends that the Pfizer-BioNTech vaccine be stored at -80 ° C to -60 ° C.
The researchers too fa-near that older people – who were given priority earlier in the Israeli vaccination campaign – may have a reduced or delayed response to vaccination due to an age-related decline in their immune function.
It is also possible that the efficacy of the vaccine will be reduced against some of the emerging viral strains, including the B.1.1.7 variant found in the UK which is -now common in Israel, and the 501Y.V2 first seen in South Africa, the researchers said.
Read more: Why the mutated coronavirus variants are so worrying: QuickTake
They will too fa-near that people with vaccines can change their behavior and adhere to public health prevention guidelines, such as body speed and alien facial wear, thus increasing viral transmission.
“In addition, viral transmission can occur in the vaccine areas themselves,” the researchers said. “Vaccination sites should be large and ventilated to reduce the likelihood of on-site transmission.”
Parts of Israel with higher disease rates and lower socioeconomic status had lower uptake even with adequate vaccination, the researchers found, noting the need to encourage citizens in those areas and make scenes even more accessible there.
The researchers investigated the need for more studies aimed at assessing the efficacy of vaccination in reducing SARS-CoV-2 transmission both on the individual and at the population level with greater follow-up. and in additional numbers.